Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort studyFrancesco Passamonti, Celestino Ferrandina, Roberto Cairoli et al.|The Lancet Haematology|2020Cited by 553
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemiaDavide Rossi, Gianluca Gaïdano, Lodovico Terzi-di-Bergamo et al.|Blood|2015Cited by 215
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemiaAdriano Venditti, Sergio Amadori, Alfonso Piciocchi et al.|Blood|2019Cited by 215
Additional lesions identified by genomic microarrays are associated with an inferior outcome in low‐risk chronic lymphocytic leukaemia patientsGian Matteo Rigolin, Antonio Cuneo, Alice Traversa et al.|British Journal of Haematology|2023Cited by 2